Showing results (381-390 of 421) with videos related to

Sort By:
Pageof 43
Blood|July 17, 2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Stephan Stilgenbauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized TrialsArndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study groupNicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, et al.
Lancet (London, England)|February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Anti-Cancer Drugs|June 6, 2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancerArndt Stahler, Volker Heinemann, Jens Neumann, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
Transplantation Direct|August 1, 2025
Association of Blood Donor-derived Cell-free DNA Levels With Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational StudyAylin Akifova, Klemens Budde, Mira Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudySebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyS Stintzing, L Miller-Phillips, D P Modest, et al.
Pageof 43